The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study

被引:206
作者
Girolami, B
Prandoni, P
Stefani, PM
Tanduo, C
Sabbion, P
Eichler, P
Ramon, R
Baggio, G
Fabris, F
Girolami, A
机构
[1] Univ Hosp Padua, Chair Internal Med 2, Dept Med & Surg Sci, Div Internal Med, Padua, Italy
[2] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany
关键词
D O I
10.1182/blood-2002-07-2201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although heparin-induced thrombocytopenia (HIT) is a known complication of intravenous unfractionated heparin (UFH), its incidence in medical patients treated with subcutaneous UFH is less well defined. To determine the incidence of HIT in this category of patients, the platelet count was performed it baseline and then every 3 +/- 1 days in 598 consecutive patients admitted to 2 medical wards and treated with subcutaneous UFH for prophylactic (n = 360). or therapeutic (n = 238) indications. The diagnosis of HIT was accepted in the case of A platelet drop of 50% or more and either the demonstration of heparin-dependent antibodies or (when this search could not be performed) the combination of the following features: (1) the absence of any other obvious clinical explanation for thrombocytopenia, (2) the occurrence of thrombocytopenia at least 5 days after heparin start, and (3) either the normalization of the platelet count within. 10 days after heparin discontinuation or the earlier. patient's death due to an unexpected thromboembolic complication. HIT. developed in 5 patients (0.8%; 95% Cl, 0.1%-1.6%); all of them belonged to the subgroup of patients who received, heparin for prophylactic.. indications. The prevalence of thromboembolic complications in patients with HIT (60%) was remarkably higher than that observed in the remaining 593 patients (3.5%), leading to an odds ratio of 40.9 (95% Cl, 5.2-162.8). Although the frequency of HIT in hospitalized medica. I patients treated with subcutaneous heparin is lower than that observed, in other clinical settings, this complication is associated with a similarly high rate of thromboembolic events. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:2955 / 2959
页数:5
相关论文
共 20 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]   HEPARIN-INDUCED IMMUNE THROMBOCYTOPENIA [J].
BABCOCK, RB ;
DUMPER, W ;
SCHARFMAN, WB .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (05) :237-241
[3]  
Caprini JA, 2002, INT ANGIOL, V21, P78
[4]   HEPARIN-INDUCED THROMBOCYTOPENIA [J].
CHONG, BH .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1992, 22 (02) :145-152
[5]  
Eichler P, 1999, THROMB HAEMOSTASIS, V81, P625
[6]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Heit, JA ;
Clagett, GP ;
Pineo, GF ;
Colwell, CW ;
Anderson, FA ;
Wheeler, HB .
CHEST, 2001, 119 (01) :132S-175S
[7]   Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range [J].
Greinacher, A ;
Eichler, P ;
Lubenow, N ;
Kwasny, H ;
Luz, M .
BLOOD, 2000, 96 (03) :846-851
[8]  
GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247
[9]   Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety [J].
Hirsh, J ;
Warkentin, TE ;
Shaughnessy, SG ;
Anand, SS ;
Halperin, JL ;
Raschke, R ;
Granger, C ;
Ohman, EM ;
Dalen, JE .
CHEST, 2001, 119 (01) :64S-94S
[10]  
KELTON JG, 1994, BLOOD, V83, P3232